High Resolution Melting Analysis for Cancer Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting susceptibility to tumor therapies, such as those targeting the EGFR pathway in colorectal cancer, are not widely adopted in clinical diagnostics due to limitations in sensitivity and specificity, particularly for mutations in genes like KRAS, BRAF, PIK3CA, and AKT1, which are crucial for determining treatment responses.
Innovation Solution
The development of High Resolution Melting (HRM) assays using specific oligonucleotides and primer pairs for amplifying and analyzing genomic DNA from patient samples to detect mutations in KRAS, BRAF, PIK3CA, and AKT1 genes, allowing for rapid and sensitive identification of hot-spot mutations, even in Formalin Fixed Paraffin Embedded (FFPE) tissues, and correlating these mutations with treatment resistance or responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional mutation screening methods (Sanger sequencing, real-time PCR, pyrosequencing) are used, then treatment response prediction can be achieved, but the methods lack sufficient sensitivity and specificity for clinical diagnostic adoption
Solution Approach 1:
The patent applies parameter changes by optimizing the PCR amplification conditions and HRM analysis parameters to enhance mutation detection capability. Specifically, the method uses optimized primer concentrations, annealing temperatures, and melting curve analysis parameters to achieve superior sensitivity and specificity compared to conventional methods, thereby resolving the contradiction between measurement precision and clinical reliability
Solution Approach 2:
The patent replaces conventional mechanical sequencing methods with a thermal-based HRM analysis system. By substituting the mechanical Sanger sequencing process with thermal melting curve analysis combined with fluorescent dye detection, the method achieves higher throughput and precision while maintaining clinical applicability, thus improving both measurement precision and clinical adoption reliability
2Measurement precision
If extensive DNA sequencing is performed to accurately detect mutations, then treatment response prediction accuracy improves, but the cost and time requirements increase significantly
Solution Approach 1:
The patent extracts only the critical melting temperature parameters from the full sequencing process. By focusing solely on the Tm differences detected during HRM analysis rather than performing complete sequence determination, the method achieves sufficient prediction accuracy while dramatically reducing analysis time and resource requirements
Solution Approach 2:
The patent applies partial action by performing only the essential HRM melting curve analysis without proceeding to full sequencing for all samples. This selective approach provides adequate precision for clinical decision-making in the majority of cases while minimizing time loss, reserving extensive sequencing only for ambiguous cases
3Adaptability or versatility
If comprehensive mutation analysis of multiple genes (KRAS, BRAF, PIK3CA, AKT1) is performed, then treatment response prediction coverage improves, but the complexity of the diagnostic procedure increases
Solution Approach 1:
The patent implements universality by developing a single HRM-based platform that can analyze multiple genes (KRAS, BRAF, PIK3CA, AKT1) using the same fundamental methodology. This multi-functional approach allows comprehensive gene coverage while maintaining procedural simplicity, as the same thermal melting analysis principles apply across all target genes
Solution Approach 2:
The patent applies segmentation by dividing the comprehensive mutation analysis into separate PCR amplification steps for each gene, followed by a unified HRM analysis. This segmentation allows targeted analysis of specific genes of interest while using a common detection platform, thereby improving adaptability without proportionally increasing overall procedure complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HRM assays provide a cost-effective, high-sensitivity, and high-specificity method for detecting genomic mutations, enabling accurate prediction of treatment responses and reducing the need for extensive sequencing, thus facilitating personalized cancer therapy.
Implementation Method 1
The method is based on the dissociation of DNA, when exposed to an increasing temperature in the presence of fluorescent dyes interacting with double-stranded DNA
Implementation Method 2
the dissociation of DNA, when exposed to an increasing temperature
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The present invention relates to a method for determining the increased likelihood of a response to a targeted treatment of a cancer disease, comprising the steps of (i) isolating genomic DNA from a patient sample (b) amplifying at least one fragment of said DNA by means of PCR with a specific pair of amplification primers (iii) determining, whether said amplified fragment has a wildtype sequence or comprises a mutation by means of a High Resolution Melting Analysis (HRM), and (iv) correlating the presence or absence of a mutation with an increased likelihood of success of said targeted treatment. Such HRM assays using genomic DNA containing the desired mutation, enable detection of 3.1% to 12.5% mutated DNA wehen mixed in wildtype background. Respective primer pairs, compositions and kits are also claimed.